泰格医药
(300347)
| 流通市值：312.55亿 | | | 总市值：475.29亿 |
| 流通股本：5.66亿 | | | 总股本：8.61亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,801,473,935.03 | 6,832,800,615.35 | 5,025,868,260.75 | 3,250,444,279.63 |
| 营业收入 | 1,801,473,935.03 | 6,832,800,615.35 | 5,025,868,260.75 | 3,250,444,279.63 |
| 二、营业总成本 | 1,644,573,250.45 | 6,312,645,254.48 | 4,559,527,495.2 | 2,942,263,124.15 |
| 营业成本 | 1,321,581,301.06 | 4,959,606,315.77 | 3,560,252,024.84 | 2,272,465,808.39 |
| 税金及附加 | 8,559,140.98 | 34,929,024.09 | 25,585,746.05 | 16,314,692.38 |
| 销售费用 | 56,191,158.6 | 234,658,095.13 | 175,449,787.82 | 107,910,230.35 |
| 管理费用 | 173,425,810.23 | 725,906,444.89 | 530,840,458.53 | 355,285,023.64 |
| 研发费用 | 62,655,948.12 | 257,643,569.77 | 191,239,953.92 | 127,004,932.88 |
| 财务费用 | 22,159,891.46 | 99,901,804.83 | 76,159,524.04 | 63,282,436.51 |
| 其中:利息费用 | - | 90,559,390.82 | - | 54,401,937.67 |
| 其中:利息收入 | - | 15,126,062.26 | - | 8,422,574.46 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 195,035,877.15 | 42,256,274.39 | 323,191,353.26 | -89,643,957.92 |
| 加:投资收益 | 36,660,390.11 | 433,815,899.7 | 440,220,795.12 | 233,000,832.99 |
| 资产处置收益 | -463,466.46 | 3,650,548.27 | 5,223,121.86 | 625,757.46 |
| 资产减值损失(新) | -572,928.54 | -38,961,326.65 | -5,401,777.73 | -4,294,719.2 |
| 信用减值损失(新) | -2,488,564.14 | 1,917,920.09 | -26,908,313.51 | -25,015,431.51 |
| 其他收益 | 20,766,535.53 | 46,585,292.33 | 26,343,546.96 | 21,404,223.43 |
| 四、营业利润 | 405,838,528.23 | 1,009,419,969 | 1,229,009,491.51 | 444,257,860.73 |
| 加:营业外收入 | 133,522.92 | 2,238,748.93 | 809,111.08 | 497,380.27 |
| 减:营业外支出 | 27,742.7 | 8,443,597.94 | 7,037,847.33 | 2,065,905.52 |
| 五、利润总额 | 405,944,308.45 | 1,003,215,119.99 | 1,222,780,755.26 | 442,689,335.48 |
| 减:所得税费用 | 75,860,662.83 | 198,158,945.47 | 131,099,588.8 | 79,861,031.64 |
| 六、净利润 | 330,083,645.62 | 805,056,174.52 | 1,091,681,166.46 | 362,828,303.84 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 330,083,645.62 | 805,056,174.52 | 1,091,681,166.46 | 362,828,303.84 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 49,043,121.13 | 887,890,076.31 | 1,020,434,157.81 | 383,337,133.84 |
| 少数股东损益 | 281,040,524.49 | -82,833,901.79 | 71,247,008.65 | -20,508,830 |
| 扣除非经常损益后的净利润 | 120,394,081.64 | 355,078,814.5 | 325,942,579.27 | 210,752,394.83 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 1.04 | 1.19 | 0.45 |
| (二)稀释每股收益 | 0.06 | 1.04 | 1.19 | 0.45 |
| 八、其他综合收益 | -87,366,018.26 | -53,653,137.05 | 9,646,423.79 | 48,983,183.82 |
| 归属于母公司股东的其他综合收益 | -63,703,960.36 | -42,027,176.87 | 8,770,477.73 | 36,845,539.93 |
| 九、综合收益总额 | 242,717,627.36 | 751,403,037.47 | 1,101,327,590.25 | 411,811,487.66 |
| 归属于母公司股东的综合收益总额 | -14,660,839.23 | 845,862,899.44 | 1,029,204,635.54 | 420,182,673.77 |
| 归属于少数股东的综合收益总额 | 257,378,466.59 | -94,459,861.97 | 72,122,954.71 | -8,371,186.11 |
| 公告日期 | 2026-04-29 | 2026-03-31 | 2025-10-29 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |